Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 3.52IPCO.TO -0.15DC.A.TO 0.3NESN-SIX 0MCK 13.94GOOG -1.34XLV 0.79TEVA 0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.45
+0.48 (1.70%)
as of Aug 25, 2026, 5:51:24 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
PAST TOP PICK

Pfizer Inc(PFE)

Apr 29, 2004
(Top Pick March 29/04. Up 2.5%.) Lots of upside potential.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$35.57

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 07, 2004
On his watch list. Have a very strong product offering. High quality management. Probably the best drug portfolio and retail pipeline.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$35.67

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 02, 2004
The inclusion in the DOW is significant and we'll give it an upward bias. One of the best pharmaceutical companies in the world. There is competition and drug pipelines are a little tougher. A little expensive.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
No
Unlock Rating
$36.00

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Apr 01, 2004
Is going to be listed in the Dow on Monday which will have a positive impact for the short term. As a multiple in the low 20's. Has decent growth, but it's less than the multiple. Probably reasonably valued and any upside would make it overvalued.
Photo of Bruce Campbell (1)Bruce Campbell (1)Unlock Rating
$35.59

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Mar 29, 2004
Has reached about a 20-year valuation low. Relatively cheap.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$35.02

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Mar 29, 2004
Have a great lineup of existing drug products and lots more in the pipeline. At about 18 X earnings. Cheap.
Photo of Rob CallanderRob Callander
Owned
Unlock Rating
$35.02

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 19, 2004
Thinks it's going to grow earnings at 15% this year.
Photo of Paul O'NeilPaul O'Neil
Owned
Unlock Rating
$33.95

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 09, 2004
(A top pick Dec 29/03. Up 7.2%.) Still likes. As far and away the best growth profile in pharmaceuticals. Growing the fastest even though it's the most expensive.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$37.30

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
DON'T BUY

Pfizer Inc(PFE)

Feb 19, 2004
Have a very good pipeline. Faces significant generic exposure for the next few years because of patent exposure. On his focus list and will probably stay there for some time.
Photo of Matt BaraschMatt Barasch
No
Unlock Rating
$37.28

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 17, 2004
Feels it is going to move substantially higher in the next 12/18 months.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$37.75

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Feb 10, 2004
Had a good run. Benefit you to wait. Buy when it is down a few dollars from current price.
Photo of Brad WillockBrad WillockUnlock Rating
$38.00

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 15, 2004
A great pharmaceutical company. Has a huge stable of drugs coming through.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$34.82

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 07, 2004
(A past top pick Dec 6/03. Up 6.7%.) Still likes it. A tremendous pipeline. Not facing a lot of patent issues. Very reasonable valuation. Will be a solid 15/20% grower.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$36.79

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 29, 2003
Pharmaceutical companies have been laggards. Should have revenue growth of about 40% and earnings at about 20% in 2004. 2 1/2% dividend.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$35.00

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Dec 12, 2003
One of the best pharmaceutical companies. The large pharmaceutical companies are increasingly facing more and more headwinds. If it reaches the upper $30's, consider selling.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
Owned
Unlock Rating
$34.40

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 736 to 750 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -1.87$101
TFPM 0$
OGC.TO -0.31$42.91
SLB -0.3$53.7
ARG.TO 0.39$8.61

Today's Top Picks

SII.TO 3.52$190.71
IPCO.TO -0.15$35.07
DC.A.TO 0.3$5.45
NESN-SIX 0$
MCK 13.94$887.73

Popular Articles

Latest Sell Signals

RKLB -1.15$67.13
INTC 0.47$87.73
MSFT 2.5$489.81
WSP.TO -2.54$189.74
CLS.TO 7.17$414.53

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like